MedTrace Logo

One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL

NCT06618313 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-06-03

No results posted yet for this study

Summary

Evaluate the Safety and Efficacy of JCXH-213 in Patients with Relapsed/Refractory B-cell non-Hodgkin Lymphoma

Conditions

  • B-Cell Non-Hodgkin Lymphoma-Recurrent
  • B-Cell Non-Hodgkin Lymphoma-Refractory

Interventions

DRUG

JCXH-213,an mRNA-LNP based in vivo CAR therapy

JCXH-213 infusion

Sponsors & Collaborators

  • Ruijin Hospital

    collaborator OTHER

  • Beijing GoBroad Hospital

    lead OTHER

Principal Investigators

  • Kai Hu, Chief Physician · Beijing GoBroad Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-27
Primary Completion
2026-08-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06618313 on ClinicalTrials.gov